title: Treatment of rheumatoid arthritis with methotrexate in Congolese patients.
abstract: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA) but data concerning the effectiveness of treatment with this compound are lacking in the Congolese population. In the present study, the evolution of RA in Congolese patients on MTX treatment is reported from before disease-modifying antirheumatic drug (DMARD) initiation till 20 months later. All consecutive DMARD-naïve RA patients (ACR 1987 criteria) attending the rheumatology unit of the University Hospital of Kinshasa from January 2008 to September 2010 were included. All were treated with MTX (started at 7.5 mg/week) and bridging steroids (started at 30mg/day). Treatment adaptations of MTX and concomitant drugs are reported as well as evolution of disease activity (DAS28-ESR), functionality (Health Assessment Questionnaire), radiological damage, and safety over 20 months. Of 98 patients recruited, more than one third were lost at follow-up. A follow-up visit at 20 months was available for 51 patients. These 48 women and 3 men had a mean age of 51.2 ± 13 years and a mean delay from symptom onset till their first visit of 3.2 years. At 20 months, the average MTX dose was 9.7 mg weekly. A second DMARD was added in three patients. The average dose of prednisone at 20 months was 7.5 mg daily. A significant improvement of DAS28 and functional disability was observed and 35.3 % of patients entered remission (DAS28 <2.6). A progression of X-ray damage was observed in one third of patients. Two patients had to stop MTX because of severe side effects and two patients developed diabetes. Methotrexate and bridging steroids therapy is effective also in sub-Saharan Africa but the average weekly MTX dose remains low. Implementation of a regular follow-up is a major issue.
authors: Unit of Rheumatology, Department of Internal Medicine, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.
authors: J J
authors: JJ
authors: Malemba
authors: J M
authors: JM
authors: Mbuyi Muamba
authors: J
authors: J
authors: Mukaya
authors: X
authors: X
authors: Bossuyt
authors: P
authors: P
authors: Verschueren
authors: R
authors: R
authors: Westhovens
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D015023:Democratic Republic of the Congo; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D011203:Poverty; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D013256:Steroids / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D013256:Steroids; D011241:Prednisone; D008727:Methotrexate
references: J Rheumatol. 1993 Mar;20(3):579-81
references: 8478878
references: Rev Rhum Mal Osteoartic. 1991 Jun;58(6):459-65
references: 1896787
references: Qual Health Res. 2007 Nov;17(9):1280-91
references: 17968044
references: Arthritis Rheum. 2003 Oct;48(10):2750-62
references: 14558079
references: J Rheumatol. 2010 Jul;37(7):1444-53
references: 20516031
references: Rheumatology (Oxford). 2000 Jan;39(1):28-33
references: 10662870
references: Br Med Bull. 2012 Sep;103(1):203-21
references: 22879627
references: Ann Rheum Dis. 2005 Nov;64(11):1582-7
references: 15860509
references: Arthritis Rheum. 2005 Feb;52(2):402-11
references: 15693010
references: J Rheumatol. 1999 Mar;26(3):743-5
references: 10090194
references: Rheumatology (Oxford). 2012 Sep;51(9):1644-7
references: 22627729
references: Arthritis Rheum. 1988 Mar;31(3):315-24
references: 3358796
references: J Virol Methods. 2000 Nov;90(2):153-65
references: 11064116
references: Ann Rheum Dis. 2011 Mar;70(3):404-13
references: 21292833
references: Arthritis Rheum. 2005 Mar;52(3):722-32
references: 15751097
references: Rheumatology (Oxford). 2004 Oct;43(10):1252-5
references: 15238643
references: Arthritis Res Ther. 2006;8(4):216
references: 16879719
references: J Rheumatol. 2005 May;32(5):796-800
references: 15868611
references: Clin Rheumatol. 2008 Jan;27(1):47-54
references: 17541812
references: Rheumatology (Oxford). 2000 Jun;39 Suppl 1:9-16
references: 11001374
references: Br J Rheumatol. 1996 Nov;35(11):1101-5
references: 8948296
references: Arthritis Rheum. 2011 Dec;63(12):3702-11
references: 21953215
references: Arthritis Rheum. 2005 Sep;52(9):2625-36
references: 16142705
references: Arthritis Rheum. 2006 Jan;54(1):26-37
references: 16385520
references: Arthritis Rheum. 1981 Oct;24(10):1308-15
references: 7306232
references: Arthritis Rheum. 2007 Apr 15;57(3):440-7
references: 17394230
references: Arthritis Rheum. 1995 Jan;38(1):44-8
references: 7818570